Anticancer agent 329 

Anticancer agent 329 is a mitochondria-targeted Podophyllotoxin (HY-15552) derivative conjugated with F16 (HY-100395), and also acts as an anticancer agent. Anticancer agent 329 accumulates in mitochondria and induces Apoptosis in a concentration-dependent manner. Anticancer agent 329 can be used in the research of liver cancer, colorectal cancer, non-small cell lung cancer and breast cancer^[1].

Anticancer agent 329 (Compound 6d) potently inhibits the proliferation of HepG2, HCT116, A549, and MDA-MB-231 cells with IC₅₀ values of 0.66 μM, 1.10 μM, 2.00 μM, and 3.31 μM respectively, and exhibits a selectivity index of 2.29 for HepG2 cells over normal QSG-7701 hepatocytes^[1].
Anticancer agent 329 (1.2-4.8 μM; 24 h) induces apoptosis in HepG2 cells in a concentration-dependent manner, with total apoptosis rates reaching 17.79% at a 4.8 μM 24-hour treatment^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

839.77

C₄₅H₄₇BrN₂O₉

3128226-38-7

O=C(OC1)[C@@H]([C@H]1[C@H]2OC(CCCCCCC[N+]3=CC=C(/C=C/C4=CNC5=C4C=CC=C5)C=C3)=O)[C@H](C6=CC(OC)=C(OC)C(OC)=C6)C(C2=C7)=CC8=C7OCO8.[Br-]

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Xu C, et al. Synthesis of mitochondria-targeted podophyllotoxin derivatives for the imaging and antiproliferation of liver cancer. Bioorganic & medicinal chemistry letters. 2026 Jul;136:130591.